Hematopoietic Cell Transplantation for Malignant Astrocytomas and Gliomas

This policy addresses hematopoietic cell transplantation (autologous and allogeneic HCT, including peripheral blood, bone marrow, or umbilical cord blood) for malignant astrocytomas and gliomas (including glioblastoma/high‑grade glioma, recurrent malignant astrocytoma, and related neuroepithelial tumors/PNETs). Coverage is subject to the member’s benefit contract and major limits/requirements — allogeneic HCT requires documented HLA compatibility, autologous HCT follows myeloablative chemotherapy and is used mainly as consolidation or salvage, HCT is considered experimental/investigational for gliomas, the policy is inactive for claims adjudication, and an Illinois pediatric coverage exception applies only to certain fully insured plans effective 2025-01-01.

"Hematopoietic cell transplantation for treatment of malignant astrocytomas and gliomas"

Sign up to see full coverage criteria, indications, and limitations.